Press & News

People are different and so is their cancer, patients should be treated individually.

2cureX’s CEO Fernando Andreu is buying shares in the company

April 27, 2021

IR

2cureX AB announces that CEO Fernando Andreu has bought 7.987 shares for approx. 0,15 MSEK.

For more information, please contact:
Fernando Andreu
Chief Executive Officer
Tel: +45 22 79 53 99
E-mail: fa@2curex.com

Certified Adviser

Redeye AB

Phone: +46 8 121 576 90

Mail: certifiedadviser@redeye.se

About 2cureX

2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D microtumors that functionally resemble the patient's tumor and identifies the approved cancer treatment that most effectively kills the patient's tumor. Immediately after the test, the patient is given the selected treatment.

The first IndiTreat® product in metastatic colorectal cancer is introduced to the European market. Subsequent products help patients at different stages of colorectal cancer and other solid cancers.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com.